CompletedPhase 1NCT04086602
Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inflazome UK Ltd
- Principal Investigator
- Jason Lickliter, MBBS, PhDNucleus Network
- Intervention
- IZD334(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2019 – 2020
Study locations (1)
- Nucleus Network, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04086602 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
See all trials for NLRP3-associated autoinflammatory disease →